These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 1026527)

  • 1. Circulatory effects of intravenous disopyramide in heart failure.
    Jensen G; Uhrenholt A
    J Int Med Res; 1976; 4(1 Suppl):42-5. PubMed ID: 1026527
    [No Abstract]   [Full Text] [Related]  

  • 2. Haemodynamics of intravenous disopyramide.
    Sutton R
    J Int Med Res; 1976; 4(1 Suppl):46-8. PubMed ID: 1026528
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effect of intravenous disopyramide on the hemodynamics of patients hospitalized in intensive care units].
    Boland J; Lisin N; Marcelle R; Carlier J
    Arch Int Pharmacodyn Ther; 1976 Nov; 224(1):145-51. PubMed ID: 1015909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-arrhythmic and haemodynamic effects of intravenous and oral disopyramide in patients with ventricular arrhythmia.
    Hulting J; Rosenhamer G
    J Int Med Res; 1976; 4(1 Suppl):90-5. PubMed ID: 1026537
    [No Abstract]   [Full Text] [Related]  

  • 5. The hemodynamic effects of Norpace. (Part II).
    Willis PW
    Angiology; 1975 Jan; 26(1 Pt 2):102-10. PubMed ID: 1115396
    [No Abstract]   [Full Text] [Related]  

  • 6. Haemodynamic effects of intravenous disopyramide in heart failure.
    Jensen G; Sigurd B; Uhrenholt A
    Eur J Clin Pharmacol; 1975 Apr; 8(3-4):167-73. PubMed ID: 1233215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study of hemodynamic and coronary effects induced by intravenous injection of disopyramide administered to coronary failure and congestive heart failure patients (author's transl)].
    Pornin M; Roland E; Lardoux H; Sellier P; Morin D; Ourbak P; Maurice P
    Therapie; 1981; 36(2):179-86. PubMed ID: 7292392
    [No Abstract]   [Full Text] [Related]  

  • 8. [Electrophysiologic and hemodynamic effects of disopyramide phosphate (author's transl)].
    Suzuki S; Kasanuki H; Onishi S; Tanaka T; Hirosawa K; Tanaka T; Abe M; Kohashi K; Taniguchi T; Matsuda M
    Kokyu To Junkan; 1981 Oct; 29(10):1079-84. PubMed ID: 6800004
    [No Abstract]   [Full Text] [Related]  

  • 9. Some aspects of the clinical pharmacology of intravenous disopyramide after myocardial infarction.
    Hillis WS; Tweddel A; Lorimer AR; Lawrie TD
    J Int Med Res; 1976; 4(1 Suppl):74-7. PubMed ID: 1026533
    [No Abstract]   [Full Text] [Related]  

  • 10. The hemodynamic effects of Norpace (Part I).
    Befeler B
    Angiology; 1975 Jan; 26(1 Pt 2):99-101. PubMed ID: 1115404
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of disopyramide on systemic and coronary hemodynamics and myocardial metabolism in patients with coronary artery disease: comparison with lidocaine.
    Kötter V; Linderer T; Schröder R
    Am J Cardiol; 1980 Sep; 46(3):469-75. PubMed ID: 7415992
    [No Abstract]   [Full Text] [Related]  

  • 12. Intravenous nicardipine in patients with chronic heart failure: a nuclear stethoscope study.
    Lahiri A; Robinson CW; Tovey J; Caruana MP; Kohli RS; Harlow BJ; Raftery EB
    Postgrad Med J; 1984; 60 Suppl 4():35-8. PubMed ID: 6527978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hemodynamic effects of disopyramide and procainamide in open-chest animals].
    Binetti G; Branzi A; Malini PL; Specchia S; Magelli C; Zannoli R; Magnani B
    G Ital Cardiol; 1978; 8(12):1314-9. PubMed ID: 738572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous disopyramide in myocardial infarction: a haemodynamic study.
    Marrott PK; Nairn PL; Hill PD; Turner G; Sharman J
    N Z Med J; 1983 Jan; 96(723):4-7. PubMed ID: 6571755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hemodynamic effects of oral disopyramide in patients with acute myocardial infarction].
    Bassan R; Miqueloti P; de Souza MA; Luz FS
    Arq Bras Cardiol; 1982 Nov; 39(5):355-7. PubMed ID: 7186390
    [No Abstract]   [Full Text] [Related]  

  • 16. Cardiohemodynamic effects of BAY a 1040 in the dog.
    Hashimoto K; Taira N; Chiba S; Hashimoto K; Endo M
    Arzneimittelforschung; 1972 Jan; 22(1):15-21. PubMed ID: 5066992
    [No Abstract]   [Full Text] [Related]  

  • 17. Haemodynamic and electrocardiographic effects of intravenous disopyramide (rythmodan) following acute myocardial infarction.
    Davies GJ; Marrott PK; Muir JR
    Br J Clin Pharmacol; 1979 Feb; 7(2):183-7. PubMed ID: 760751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Toxic and hemodynamic effects of aprindine in the dog. Comparison with other anti-arrhythmia agents].
    Lisin N; Carlier J
    Acta Cardiol; 1974; Suppl 18():117-30. PubMed ID: 4547497
    [No Abstract]   [Full Text] [Related]  

  • 19. [Comparison of the effects of disopyramide and hydroquinidine in animals].
    Lisin N; Carlier J
    Arch Mal Coeur Vaiss; 1973 Oct; 66(10):1329-35. PubMed ID: 4207476
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparative haemodynamic effects of lidocaine, mexiletine, and disopyramide.
    Beltrame J; Aylward PE; McRitchie RJ; Chalmers JP
    J Cardiovasc Pharmacol; 1984; 6(3):483-90. PubMed ID: 6202976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.